Table 2.
Disorders associated with microangiopathic haemolytic anaemia and thrombocytopenia.32
| Primary thrombotic microangiopathy syndromes |
| Hereditary disorders |
| ADAMTS13 deficiency-mediated TMA (also known as TTP) |
| Complement-mediated TMA (also known as atypical HUS) |
| Metabolism-mediated TMA (e.g. B12 deficiency) |
| Acquired disorders |
| ADAMTS13 deficiency-mediated TMA (also known as TTP) |
| Shiga toxin-mediated TMA (also known as Shiga toxin-HUS) |
| Drug-induced TMA |
| Complement-mediated TMA |
| Other disorders |
| Systemic infection |
| Systemic cancer |
| Severe pre-eclampsia, eclampsia, HELLP syndrome |
| Severe hypertension |
| Autoimmune disorders (e.g. systemic lupus erythematosus, systemic |
| sclerosis, antiphospholipid antibody syndrome) |
| Haematopoietic stem-cell or organ transplantation |
ADAMTS13: A disintegrin and metalloproteinase with thrombospondin motifs 13; HUS: hemolytic uremic syndrome; TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura.